The legal dispute dates to late 2014, when Cynviloq was supposedly on track to be cleared by the U.S. Food and Drug Administration. Cynviloq was modeled after Abraxane, with a few tweaks to the drug’s design so that it could be administered to patients more efficiently and at a lower cost. Abraxane, according to court documents, sells for $1,378 per dose in the U.S. and has no direct competition. In South Korea, however, the price is $270 per dose because of competition from Cynviloq, which is sold there for $180 per dose under the name Genexol-PM.

Source: Los Angeles Times April 04, 2019 04:18 UTC